Last reviewed · How we verify

Zarontin — Competitive Intelligence Brief

Zarontin (Ethosuximide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Succinimide. Area: Neuroscience.

marketed Succinimide Voltage-dependent T-type calcium channel subunit alpha-1G Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Zarontin (Ethosuximide) — Pfizer. Suppresses paroxysmal three cycle per second spike and wave activity associated with absence seizures.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Zarontin TARGET Ethosuximide Pfizer marketed Succinimide Voltage-dependent T-type calcium channel subunit alpha-1G 1960-01-01
Zarontin ETHOSUXIMIDE Pfizer marketed Anti-epileptic Agent [EPC] Voltage-dependent T-type calcium channel subunit alpha-1G 1960-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Succinimide class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zarontin — Competitive Intelligence Brief. https://druglandscape.com/ci/zarontin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: